Possibilities for the correction of functional disorders of the biliary tract and parasitic infestations in young children using the plant complex Vormil Phyto

Recently, there has been a significant growth in parasitic invasions among young children. At a younger age, parasitic infestations most often occur “under the mask” of gastroenterological pathology. At this age range, according to the domestic and world literature, functional diseases prevail. In May 2016, at the week of American gastroenterology, the Rome criteria IV were adopted. According to the the Rome criteria IV, as well as in the previous editions, it is suggested to prescribe therapy on the basis of the predominant symptom principle, giving preference to so-called complementary and alternative medicine, and, in particular, phytotherapy as additional therapy for the disease, but all also from the standpoint of evidence. The first such combined phytocomplex, which attracted interest from clinical researchers and patients, is Vormil Phyto — a mix of extracts of thirteen plants. The purpose of our research was the improvement of therapeutic approaches to the correction of the combined functional pathology of the biliary tract and parasitic invasion, as well as unassociated pathology of the biliary tract using phytocomplex Vormil Phyto in the main treatment regimens. Sixty children were divided into three groups: the first group with combined functional disorder of the biliary tract and parasitic infestation; the second group with a functional biliary tract disorder, received the phytocomplex Vormil Phyto; the third group with a functional biliary tract disorder, received traditional therapy. In the course of the research, data were obtained that indicate the effectiveness of the phytocomplex Vormil Phyto, which has not only an antihelmintic effect, but also normalizes the kinetics of the biliary tract that improves appetite rapidly and does not induce dyspeptic symptoms at earlier terms

Correction of metabolic disorders in acetonemic syndrome in children with functional disorders of the biliary tract

Background. Acetonemic syndrome (AS) is one of the common pathological conditions in children. The most important part of the therapy for AS is to prevent the metabolic disorders in acetonemic crisis in children. Purpose — to study the effectiveness of Gepargin® in the treatment of children with acetonemic syndrome and to assess the dynamics of clinical and laboratory indicators. Materials and methods. We have analyzed the results of the medical examination and treatment of 40 children aged 3–10 years with AS and functional disorders of the biliary tract. The survey was conducted according to the generally accepted scheme [6]. To determine the level of ketone bodies in urine, a standard laboratory method for determining acetoacetate in urine was used. The degree of ketonuria was recorded from “+” to “++++”. All patients received basic therapy, according to the unified treatment protocols, and Gepargin®. The contents of the vial were diluted in half a glass (100 ml) of drinking water and taken in 3–4 doses during the day. Duration of treatment was 5 days (before arresting the acetonemic crisis). The effectiveness of the therapy was assessed by the dynamics of complaints, state of health, clinical symptoms and laboratory data. Results. During the observation, we noted positive dynamics in the course of acetonemic syndrome. On admission to the hospital, 17 (42.5 %) children had ketonuria “++++”, 15 children (37.5 %) — “+++”, 3 (7.5 %) — “++”, and 5 (12.5 %) — “+”. In the process of Gepargin® treatment, we noted a significant decrease (by 76.5 %) in the number of children with ketonuria “++++”, and by 87 % — with ketonuria “+++”. From the 3rd day of Gepargin® treatment, none of the children had ketonuria. Conclusions. The effectiveness of Gepargin® in the comprehensive therapy of AS in children consisted in the relief of clinical symptoms. This use of this drug is pathogenetically substantiated for the correction of metabolic disorders in ketoacidosis. Gepargin® is well tolerated, it is convenient for the use in children from an early age. The results of this observation suggest using Gepargin® in basic therapy of acetonemic disorders in childhood

Functional disorders of the biliary tract in children: issues of diagnosis and correction from the position of the Rome IV criteria

More than 80 % of children with digestive system di­seases have various disorders of the hepatobiliary system. Given the fact that in the pediatric population, abnormalities or structural features of the bile ducts and gallbladder are being detected more often, it is recommended to differentiate dyskinesias by functional state of the biliary system — hypomotor (hypokinetic) and hypermotor (hyperkinetic). According to many authors, the most common children’s form is hypermotor (hyperkinetic) dyskinesia. Violations of synchronization in the work of the gastrointestinal tract and sphincter apparatus underlie the functional disorders of the biliary tract (FDBT) and are the cause of clinical symptoms. To date, there are general non-drug and drug-based approaches to the treatment of FDBT and algorithms recommended in Rome IV criteria. Pharmacotherapy should be aimed at relieving smooth muscle spasm and restoring motor activity of the gallbladder, as well as at normali­zing the rheological properties of the bile. Given the above relevance of therapy for FDBT, our attention was attracted by the combined dietary supplement of Viador syrup. The aim of our study was to modify therapeutic approaches to the correction of the functional pathology of the biliary tract and the feasibility of using the combined Viador phytopreparation in the main treatment regimens. This research confirmed the therapeutic efficacy of the combined herbal remedy Viador which has a number of useful qualities differentiating it among other herbal preparations whose effectiveness has been proven by positive clinical dynamics, additional research methods. That allows you to widely use it in the treatment of FDBT

Issues of therapy for biliary pathology in children: the choice of the optimal solution

Background. Diseases of the hepatobiliary system are one of the most important problems of pediatric gastroentero­logy. Lesions of the biliary tract are associated with persistent changes in lipid metabolism that contributes to the prolonged cholestasis and to the progression of the biliary pathology. The purpose of this study was to evaluate the efficacy and safety of Ursofalk® in the comprehensive therapy of biliary tract diseases and comorbid pathology in children. Materials and methods. The results of examination and integrated treatment of 55 children aged 5 to 18 years (31 girls and 24 boys) with diseases of the biliary tract and comorbid pathology were analyzed. The criteria for inclusion of patients in the study were: the pre­sence of diseases of the biliary tract accompanied by biliary sludge and blood lipid disorders. Diagnostic complex included: analysis of clinical data, ultrasound examination of abdominal organs, biochemical blood analysis (liver tests, lipid disorders). Depending on the comorbid pathology, all children received comprehensive treatment within a month. Patients were divided into two groups depending on choleretic therapy: group 1 (main) received conventional cholagogues, group 2 (comparison) — Ursofalk®. Licensed software products (Statistica, Excel) were used for statistical processing of the obtained data. Results. By the end of the treatment with Ursofalk® we observed positive dynamics in patients’ condition and laboratory indicators. In patients who received Ursofalk®, the manifestations of pain syndrome and dyspepsia completely disappeared. Children from the comparison group still had pain syndrome, a feeling of heaviness in the right upper quadrant and dyspepsia. The use of Ursofalk® normalized the parameters of the bile structure and the biochemical parameters of lipid metabolism. We registered a significant (p < 0.05) decrease in the incidence of impaired bile homogeneity — by 65.5 % in children from the main group. In children of the comparison group, it decreased only by 27.3 %. Positive dynamics of biochemical parameters was observed in both groups of patients, but with significant changes (p < 0.05) in the group of children taking Ursofalk®. Conclusions. Ursodeoxycholic acid (UDCA) use is pathogenetic justified for the correction of functional and metabolic disorders in biliary and comorbid pathologies in children. Ursofalk® administration in the comprehensive therapy of the diseases of the biliary system in children led to the rapid regression and relief of clinical symptoms and the improvement of laboratory-instrumental indicators. Ursofalk® is a reference product of UDCA. Availability of the officinal form of Ursofalk® in a special form for children (suspension) allows UDCA to be used in childhood, starting from the first days of life

Diarrhea in young children: clinical picture, diagnosis, principles of therapy

Many diseases in infants and young children are accompanied by the development of diarrheal syndrome. As a result, there are organic lesions and functional disorders in the intestine. It is well known fact that 1.4 billion children under 5 years in the world suffer from acute diarrhea, and 123 million of them are forced to seek medical help urgently, 9 million require inpatient care, and 1.8 million children die from dehydration. In this connection, the choice of therapeutic regimen remains urgent. Medications that slow intestinal motility (loperamide) are contraindicated in acute diarrhea in children, since the risk of side effects including ileus, drowsiness, nausea (mortality to 1 %) is high. Probiotics are living microbial drugs commonly used to prevent acute diarrhea. A large number of researches have been conducted, and results of meta-analyzes have been published that have revealed the effect of Escherichia coli strain Nissle 1917 (Mutaflor) in reducing the duration of diarrhea in children with acute gastroenteritis. Escherichia coli strain Nissle 1917 is one of the three bacteria in the world, which is better characterized at the molecular-biological level, the most investigated non-pathogenic and genetically stable strain in the world with 100-year history, having a genetic map, the genome of which is completely sequenced, genetic loci are deterministic. The product is included into the German Collection of Microorganisms and Cell Cultures (DSMZ). The purpose of our study was to improve the therapeutic approaches to the correction of diarrheal syndrome using Escherichia coli strain Nissle 1917 (Mutaflor) in the main treatment regimens. Seventy four children were examined and divided into two groups: the first group — children with diarrheal syndrome, who additionally received Mutaflor from the first day, the second group — children with diarrheal syndrome, who received traditional therapy. As a result of the study, the data were obtained proving the effectiveness of Escherichia coli strain Nissle 1917 (Mutaflor) in the treatment of diarrhea in young children, its beneficial effect not only on intestinal microflora and normalization of intestinal kinetics, but also on faster improvement of clinical symptoms, which allows recommending it to children from the first months of life

Experience of using silicon-containing enterosorbents in relieving diarrhea syndrome in children

This article deals with the pathological conditions in children with diarrhea syndrome. Pathogenetic mechanisms of diarrhea, peculiarities of clinical and laboratory manifestations in various diseases are described. The main methods of diarrhea treatment are presented, mechanisms of sorption therapy action are consi­dered. The classification of enterosorbents used in clinical pediatric practice is given. The characteristics of Apsorbin sashe, which is registered in Ukraine as food supply with enterosorption action, is given. The article presents the results of Apsorbin sashe use in the therapy of children with diarrhea type of irritated bowel syndrome and in the convalescents of the gastro-intestinal infections